Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLB | Q8NCG7 | 3/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 10/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | DDHD2 | O94830 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719693 | 0.99 | TRPM8 (0.41) | DAGLBDAGLATRPM8SERPINE1DDHD2 | |
| SCHEMBL1719689 | 0.99 | DAGLB (0.40) | DAGLBDAGLATRPM8SERPINE1DDHD2 | |
| SCHEMBL1719691 | 0.93 | DAGLB (0.39) | DAGLBDAGLATRPM8SERPINE1DDHD2 | |
| SCHEMBL1719436 | 0.92 | DAGLB (0.39) | DAGLBDAGLATRPM8SERPINE1DDHD2 | |
| SCHEMBL1719005 | 0.87 | ACHE (0.38) | DAGLBDAGLASERPINE1DDHD2SCN9A | |
| SCHEMBL15071818 | 0.85 | CASR (0.40) | — | |
| SCHEMBL1719110 | 0.82 | IDH1 (0.42) | DAGLBDAGLAIDH1 | |
| SCHEMBL1720106 | 0.81 | ACHE (0.36) | — | |
| SCHEMBL15075636 | 0.80 | DAGLB (0.40) | DAGLBDAGLATRPM8SERPINE1DDHD2 | |
| SCHEMBL1719229 | 0.80 | FFAR4 (0.44) | DAGLBDAGLASERPINE1DDHD2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, VPS4B, PIK3C2A | DAGLB 2331/4885DAGLA 2871/4885TRPM8 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.